OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

December 6th 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Dr Liu on the TRUST-II Trial of Taletrectinib in ROS1+ NSCLC

December 6th 2024

Stephen V. Liu, MD, discusses updated data from the phase 2 TRUST-II trial investigating taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Stein on the Impact of Revumenib on Survival Outcomes in KMT2A-Rearranged R/R Acute Leukemia

December 6th 2024

Eytan M. Stein, MD, discusses how the FDA approval of revumenib could improve survival outcomes in KMT2A-rearranged relapsed/refractory acute leukemia.

Dr Stearns on the Role of Carboplatin in Early-Stage TNBC

December 6th 2024

Vered Stearns, MD, discusses the role of carboplatin in early-stage triple-negative breast cancer according to results from the phase 3 PEARLY trial.

Dr Postow on the Potential Role for Triplet Regimens in Melanoma

December 5th 2024

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

Dr Patel on the Utility of the IPS Test in Solid Tumors

December 5th 2024

Sandip P. Patel, MD, discusses the Immune Profile Score and how it may be used to inform decisions with immune checkpoint inhibitor therapy in solid tumors.

Dr Senan on the FDA Approval of Durvalumab for LS-SCLC

December 4th 2024

Suresh Senan, MRCP, FRCR, PhD, discusses the significance of the FDA approval of durvalumab for patients with limited-stage small cell lung cancer.

Dr Schram on the FDA Approval of Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

December 4th 2024

Alison Schram, MD, discusses the FDA approval of zenocutuzumab in non–small cell lung cancer and pancreatic cancer harboring NRG1 fusions.

Dr Kumar on Key Treatment Considerations for Myeloma Following NCCN Guideline Updates

December 4th 2024

Shaji Kumar, MD, discusses notable therapy considerations for multiple myeloma following the 2024/early 2025 NCCN guidelines update.

Dr Kalinsky on the postMONARCH Study in HR+/HER2– Advanced Breast Cancer

December 4th 2024

Kevin Kalinsky, MD, MS, discusses outcomes of the phase 3 postMONARCH study in hormone receptor–positive, HER2-negative advanced breast cancer.

Dr Sonpavde on the AMBASSADOR Trial in Muscle-Invasive Urothelial Cancer

December 4th 2024

Guru P. Sonpavde, MD, discusses the AMBASSADOR trial of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma.

Dr Deek on Vismodegib Plus Radiation in Locally Advanced Unresectable Basal Cell Carcinoma

November 29th 2024

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

Dr Schmid on Pembrolizumab Plus Chemotherapy in High-Risk, Early-Stage TNBC

November 29th 2024

Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.

Dr Sonpavde on the Implications of the NIAGARA Trial Regimen in Bladder Cancer

November 27th 2024

Guru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.

Dr Rimm on the Effect of Inaccurate HER2 IHC Testing for Patients With Breast Cancer

November 27th 2024

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.

Dr Kamath on the Rise in Incidence of Pancreatic Cancer

November 27th 2024

Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.

Dr Moore on Key 2024 Updates in FRα+ Ovarian Cancer Management

November 27th 2024

Dr Kumar on the 2024/2025 NCCN Treatment Updates in Myeloma

November 27th 2024

Shaji Kumar, MD, discusses 2024 updates made to the NCCN guidelines for multiple myeloma treatment, as well as the first 2025 updates.

Dr Sharma on the Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

November 27th 2024

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.

Dr Tawagi on the Growing Role of Precision Medicine in Prostate Cancer

November 27th 2024

Karine Tawagi, MD, discusses the use of targeted therapies in the management of metastatic prostate cancer.